Adalimumab for adults with non-infectious uveitis
Part of Eyes & vision, Skin clinical trials.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have active non-infectious uveitis (inflammation in the middle or back of the eye).
- You must have been taking oral steroids (like prednisone) for at least 2 weeks before the study starts.
- You cannot have certain other eye conditions, like diabetic retinopathy or macular degeneration, that are not related to uveitis.
- You must agree to avoid pregnancy or sperm donation during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This study compares two medicines—adalimumab and tocilizumab—to see which works better and is safer for severe “uveitis” in people with Behçet’s disease. It’s meant for adults whose eye inflammation threatens their sight.
Hear when a new Adult Non-infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.